Release issued 14th March 2006

Technology Catalysts International, consultants to the pharmaceutical industry, announced that its research on trends and developments in drug delivery has identified a breakthrough technology that accelerates pharmaceutical product market introductions by generic and drug delivery companies.

This development is particularly relevant to producers of drugs offered in the form of orally disintegrating tablets ("ODTs"), a $2.4 billion market. They are now able to offer the same drug in the form of an "orally-dissolving strip," also known as an Oral Thin Film ("OTF"), with the filing of an Abbreviated New Drug Application ("ANDA") with the US Food and Drug Administration ("FDA"). This is a major cost of goods saver for generics. The FDA has approved the change in dosage form for drug products as long as there are no questions about the safety or effectiveness of the product. This requires that the uses, dosage and route of administration of the proposed drug product are the same as the listed drug product. This was the basis on which Pepcid AC(R) could also be offered in the form of an OTF. In Technology Catalysts' recently-released report on "Orally Disintegrating Tablet and Film Technologies" (3rd Edition), the company identified over 15 companies actively developing OTF delivery technologies that enable the shift from a tablet form to a fast-dissolving and highly water-soluble wafer or film. In addition, the report identifies nine launched OTF pharmaceutical products as well as forty-seven OTF products in the pipeline being developed by 12 companies

The development is driven by companies such as APR Applied Pharma Research S.A. ("APR"), a leading Swiss R&D company focusing on innovative drug delivery. In conjunction with Labtec GmbH, APR has developed a novel OTF technology called RapidFilm(TM). Dr. Paulo Galfetti, Head of Licensing & Business Development states that RapidFilm offers unique potential to deliver a variety of drugs, particularly when a fast onset of action is required. Classes of drugs that can benefit from delivery via the RapidFilm system include hypnotics, anxiolytics, antiemetics, NSAIDs and pain killers, 5HT1 agonists for migraine treatment, antiallergics, antacids, vitamins, minerals, and treatments for the oral cavity.

Technology Catalysts forecasts the market for drug products in oral thin film formulations to be valued at $500 million in 2007 and could reach $2 billion by 2010.

http://www.labtec-pharma.com/html/licensing_opp_rapid.html

(26th November 2008) tesa AG Acquires Labtec GmbH

(4th August 2008) Ondansetron RapidFilm™ licensed to BioAlliance Pharma for Europe

(29th January 2008) APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") Announce the Successful Completion of the Pilot Bioequivalence Study of Their Donepezil RapidFilm

(15th January 2008) Successful completion of Pivotal Bioequivalence study for Ondansetron RapidFilm

(25th April 2007) Labtec's next generation pain patch successful in clinical studies